S. Kulzhanova, M. Konkayeva, Z. Smagulova, Nazira N. Beisenbieva, G. Tuleshova, A. Utegenova, G. O. Turebaeva, Gaukhar A. Nurakhmetova
{"title":"法匹拉韦治疗Covid-19的回顾性分析","authors":"S. Kulzhanova, M. Konkayeva, Z. Smagulova, Nazira N. Beisenbieva, G. Tuleshova, A. Utegenova, G. O. Turebaeva, Gaukhar A. Nurakhmetova","doi":"10.2478/jbcr-2022-0010","DOIUrl":null,"url":null,"abstract":"Summary One of the potential therapeutic agents for treating COVID-19 is favipiravir (FPV). This retrospective study compared the treatment of COVID-19 with (FVP group) or without (control group) favipiravir. Demographic characteristics and initial clinical indicators in the two groups were comparable. The level of oxygen saturation, respiratory rate, and prevalence of chest pain in the FVP group returned to normal significantly earlier (on the seventh day) compared to the control group (p<0.05). Improvement of patients’ condition in the FVP group occurred significantly earlier than in the control group (p <0.001). In conclusion, FVP treatment’s efficacy was higher than the control management strategy and established an individualized set of therapeutic agents. However, more detailed studies are needed to evaluate the efficacy of COVID-19 treatment with favipiravir fully.","PeriodicalId":15099,"journal":{"name":"Journal of Biomedical and Clinical Research","volume":"12 1","pages":"74 - 78"},"PeriodicalIF":0.0000,"publicationDate":"2022-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":"{\"title\":\"A Retrospective Analysis of Treatment of Covid-19 with Favipiravir\",\"authors\":\"S. Kulzhanova, M. Konkayeva, Z. Smagulova, Nazira N. Beisenbieva, G. Tuleshova, A. Utegenova, G. O. Turebaeva, Gaukhar A. Nurakhmetova\",\"doi\":\"10.2478/jbcr-2022-0010\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Summary One of the potential therapeutic agents for treating COVID-19 is favipiravir (FPV). This retrospective study compared the treatment of COVID-19 with (FVP group) or without (control group) favipiravir. Demographic characteristics and initial clinical indicators in the two groups were comparable. The level of oxygen saturation, respiratory rate, and prevalence of chest pain in the FVP group returned to normal significantly earlier (on the seventh day) compared to the control group (p<0.05). Improvement of patients’ condition in the FVP group occurred significantly earlier than in the control group (p <0.001). In conclusion, FVP treatment’s efficacy was higher than the control management strategy and established an individualized set of therapeutic agents. However, more detailed studies are needed to evaluate the efficacy of COVID-19 treatment with favipiravir fully.\",\"PeriodicalId\":15099,\"journal\":{\"name\":\"Journal of Biomedical and Clinical Research\",\"volume\":\"12 1\",\"pages\":\"74 - 78\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"2\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Biomedical and Clinical Research\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2478/jbcr-2022-0010\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Biomedical and Clinical Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2478/jbcr-2022-0010","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
A Retrospective Analysis of Treatment of Covid-19 with Favipiravir
Summary One of the potential therapeutic agents for treating COVID-19 is favipiravir (FPV). This retrospective study compared the treatment of COVID-19 with (FVP group) or without (control group) favipiravir. Demographic characteristics and initial clinical indicators in the two groups were comparable. The level of oxygen saturation, respiratory rate, and prevalence of chest pain in the FVP group returned to normal significantly earlier (on the seventh day) compared to the control group (p<0.05). Improvement of patients’ condition in the FVP group occurred significantly earlier than in the control group (p <0.001). In conclusion, FVP treatment’s efficacy was higher than the control management strategy and established an individualized set of therapeutic agents. However, more detailed studies are needed to evaluate the efficacy of COVID-19 treatment with favipiravir fully.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
